Prime Medicine (PRME) Total Non-Current Liabilities (2023 - 2026)
Prime Medicine (PRME) posted Total Non-Current Liabilities of $200.0 million for Q1 2026, down 1.88% on a QoQ basis from $203.9 million in Q4 2025, and down 4.4% year-over-year from $209.2 million in Q1 2025.
Prime Medicine (PRME) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Prime Medicine's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $200.0 million for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 4.4% year-over-year to $200.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (down 4.4% YoY) and the FY2025 annual result came in at $203.9 million, up 47.34% from the prior year.
- Total Non-Current Liabilities was $200.0 million for Q1 2026 at Prime Medicine, down from $203.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $209.2 million in Q1 2025 and bottomed at $57.1 million in Q2 2024.
- A 4-year average of $148.0 million and a median of $169.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 260.93% — and 2026, when it slipped 4.4%.
- Prime Medicine's Total Non-Current Liabilities stood at $60.8 million in 2023, then jumped by 127.64% to $138.4 million in 2024, then jumped by 47.34% to $203.9 million in 2025, then retreated by 1.88% to $200.0 million in 2026.
- Business Quant data shows PRME's Total Non-Current Liabilities at $200.0 million in Q1 2026, $203.9 million in Q4 2025, and $205.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | 200.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200.03 Mn |
| Dec 31, 2025 | 203.87 Mn |
| Sep 30, 2025 | 205.19 Mn |
| Jun 30, 2025 | 206.15 Mn |
| Mar 31, 2025 | 209.24 Mn |
| Dec 31, 2024 | 138.36 Mn |
| Sep 30, 2024 | 137.28 Mn |
| Jun 30, 2024 | 57.12 Mn |
| Mar 31, 2024 | 61.62 Mn |
| Dec 31, 2023 | 60.78 Mn |